In a large trial, patients taking the experimental pill lost an average of 12% of their body weight.

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Embecta Corp. achieves record Q3 2025 revenue, raises EPS guidance, and highlights GLP-1 partnerships, debt reduction, and free cash flow growth.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

The brand known for its drink mix-ins is launching its first protein shake, while a cocktail mix maker is bringing Bloody ...

For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo Nordisk A/S (NYSE: NVO) saw its stock drop nearly 22% on July 29 after lowering ...

GLP-1s have been a hot topic, now people are raising concerns about the side effects. From loose skin and dull complexions to hair loss and more. Aesthetic ...